Myeloperoxidase release after allergen-specific conjunctival challenge

Area of Science:

• Ophthalmology
• Allergy and Immunology
• Inflammation Research

Background:

• Allergen-specific conjunctival challenge (ASCC) is a model for allergic inflammation.
• Neutrophils infiltrate the conjunctiva after ASCC, releasing enzymes like myeloperoxidase (MPO).
• The effect of ASCC on MPO release and the role of immunotherapy (IT) were previously unknown.

Purpose of the Study:

• To determine if ASCC induces MPO release in allergic patients.
• To investigate the impact of Dactylis glomerata immunotherapy on MPO release following ASCC.

Main Methods:

• Adults with seasonal allergic rhinoconjunctivitis (Dactylis glomerata-sensitive) and healthy controls were studied.
• Patients were divided into non-immunotherapy (not-IT) allergic and immunotherapy (IT)-treated groups.
• ASCC was performed, and MPO levels were measured using an enzyme immunoassay.

Main Results:

• MPO levels were significantly elevated 30 minutes post-ASCC in the not-IT allergic group compared to healthy controls (p<0.001).
• The IT-allergic group showed significantly lower MPO levels than the not-IT group (p<0.001) but higher than nonallergic subjects (p<0.001).

Conclusions:

• ASCC demonstrably leads to MPO release in allergic individuals.
• Immunotherapy appears to modulate MPO release following allergen challenge, indicating a potential anti-inflammatory effect.